AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

The data showed that Koselugo met its primary endpoint, demonstrating a statistically significant and clinically meaningful ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

Shares of AstraZeneca PLC AZN inched up 0.05% to £99.90 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 1.22% to 8,025.77.

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

Four analysts surveyed by Zacks expected $13.04 billion. Astrazeneca shares have decreased nearly 4% since the beginning of the year. The stock has climbed 1% in the last 12 months.

Additionally, AstraZeneca increased its guidance for the fiscal year ... In another report released today, Barclays also maintained a Buy rating on the stock with a £140.00 price target. TipRanks ...